Killer Cells, Natural
Research News and Information

Sunday, November 22, 2009

Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.

29 Nov 2009 Transforming growth factor-beta (TGF-beta) is a cytokine with potent immunosuppressive effects and is overexpressed in many tumors. Therefore, development of molecules able to inhibit TGF-beta is of paramount importance to improve the efficacy of ... Read more...

In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.

31 Oct 2009 Cell surface expression of MHC class I molecules by tumor cells is determinant in the interplay between tumor cells and the immune system. Nevertheless, the mechanisms which regulate MHCI expression on tumor cells are not clear. We previously showed ... Read more...

KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

24 Oct 2009 Human killer cell immunoglobulin-like receptors (KIRs) are distinguished by expansion of activating KIR2DS, whose ligands and functions remain poorly understood. The oldest, most prevalent KIR2DS is KIR2DS4, which is represented by a variable ... Read more...

Latest indexed articles for 'Killer Cells, Natural'

These are the very latest articles for this heading:

• Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. 29 Nov 2009
• In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. 31 Oct 2009
• KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. 24 Oct 2009
• CD94 defines phenotypically and functionally distinct mouse NK cell subsets. 13 Oct 2009
• Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. 13 Oct 2009
• In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 13 Oct 2009
• Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab. 13 Oct 2009
• In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. 10 Oct 2009
• How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. 6 Oct 2009
• Distinct conformations of Ly49 natural killer cell receptors mediate MHC class I recognition in trans and cis. 6 Oct 2009
• T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. 4 Oct 2009
• Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. 29 Sep 2009
• NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. 29 Sep 2009
• PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by human NK cells via autocrine IFN-beta. 29 Sep 2009
• The developmental role of natural killer cells at the fetal-maternal interface. 29 Sep 2009
• A defining factor for natural killer cell development. 29 Sep 2009
• Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. 29 Sep 2009
• Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. 29 Sep 2009
• Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. 26 Sep 2009
• Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. 13 Sep 2009

See a longer list of these articles.

Technical information about 'Killer Cells, Natural'

Definition: Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T-CELLS and B-CELLS, NK cells are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.

Descriptor UI: D007694

Alternative terms: Killer Cells, Natural; Natural Killer Cells; Cell, Natural Killer; Cells, Natural Killer; Killer Cell, Natural; Natural Killer Cell; NK Cells; Cell, NK; Cells, NK; NK Cell;

Related Mesh Headings: Receptors, Natural Killer Cell;

Allowable Qualifiers: classification; cytology; drug effects; enzymology; immunology; metabolism; microbiology; parasitology; pathology; physiology; radiation effects; radiography; radionuclide imaging; secretion; transplantation; ultrastructure; ultrasonography; chemistry; virology;

Tree Number: A11.118.637.555.567.537; A15.145.229.637.555.567.537; A15.382.490.555.567.537;

History Note: 1983

Technical Notes: do not confuse with NATURAL KILLER T-CELLS; if subpopulations are discussed, coordinate IM with LYMPHOCYTE SUBSETS (IM)